Clinical Trial in Princeton Examining New Smoking Cessation Drug

PRINCETON, NJ (SBN) — Researchers at the Global Medical Institutes in Princeton, NJ are participating in a Phase 3 trial of a new drug that may help smokers who failed at least one previous attempt to stop smoking with or without therapeutic support.

The drug is cytisinicline, a naturally derived investigational treatment that is believed to aid in smoking cessation. Cytisinicline is structurally like nicotine and works by binding to the nicotine receptor in the brain, functioning as a partial agonist and antagonist.

In this episode of SBN Newsmakers, host Steve Lubetkin chats with Dr. Sanjay Varma, MD, one of the researchers working on the ORCA-3 drug trial investigating cytisinicline.

SBN Newsmakers now includes closed-captioning for the deaf or people with a hearing loss. Click the “CC” button on the video player to activate closed-captions.

The Global Medical Institutes is recruiting participants for the ORCA-3 trials. For more information, visit or call the Global Medical Institutes at (609) 921-3555.

About the Guest

Dr. Sanjay Varma, MD

Dr. Sanjay Varma is a board-certified adult and geriatric psychiatrist with over 20 years of experience treating a broad array of psychiatric disorders. Dr. Varma is a graduate of the UMDNJ Robert Wood Johnson Medical School where he also completed his residency training in Adult Psychiatry as well as Geriatric Psychiatry Fellowship.

Prior to joining Princeton Medical Institute, Dr. Varma was a psychiatrist at Penn Medicine, Princeton House Behavioral Health in Princeton and Actify in Princeton. Dr. Varma believes in building a strong rapport with his clients and their families to deliver the best care.